Study details
Enrolling now
Studying TAK-243 in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT IDNCT06223542ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
95
Study length
about 1.1 years
Ages
18+
Locations
1 site in MD
What this study is about
This trial is testing the safety and best dose of a drug called TAK-243 in people with advanced cancer. TAK-243 is an inhibitor that may help stop cancer cells from growing and surviving.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take UAE Inhibitor TAK-243
- 2.Undergo Biopsy Procedure
- 3.Undergo Biospecimen Collection
- +3 more
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: Maximum tolerated dose (MTD), Recommended phase 2 dose
Secondary: Pharmacodynamic (PD) variables
Procedures
biopsy, diagnostic, imaging
Body systems
Oncology